Academic Journal
Construction of VSVΔ51M oncolytic virus expressing human interleukin-12.
| Τίτλος: | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12. |
|---|---|
| Συγγραφείς: | Abdulal RH; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Biological Science, Faculty of Science, King AbdulAziz University, Jeddah, Saudi Arabia., Malki JS; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia., Ghazal E; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia., Alsaieedi AA; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia., Almahboub SA; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia., Khan MY; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Biological Science, Faculty of Science, King AbdulAziz University, Jeddah, Saudi Arabia., Alsulaiman RM; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia., Ghaith MM; Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia., Abujamel TS; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia., Ganash M; Department of Biological Science, Faculty of Science, King AbdulAziz University, Jeddah, Saudi Arabia., Mahmoud AB; College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.; Strategic Research and Innovation Laboratories, Taibah University, Madinah, Saudi Arabia., Alkayyal AA; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia., Hashem AM; Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.; Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. |
| Πηγή: | Frontiers in molecular biosciences [Front Mol Biosci] 2023 May 15; Vol. 10, pp. 1190669. Date of Electronic Publication: 2023 May 15 (Print Publication: 2023). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101653173 Publication Model: eCollection Cited Medium: Print ISSN: 2296-889X (Print) Linking ISSN: 2296889X NLM ISO Abbreviation: Front Mol Biosci Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Lausanne : Frontiers Media S.A., [2014]- |
| Περίληψη: | The use of oncolytic viruses (OVs) in combination with cytokines, such as IL-12, is a promising approach for cancer treatment that addresses the limitations of current standard treatments and traditional cancer immunotherapies. IL-12, a proinflammatory cytokine, triggers intracellular signaling pathways that lead to increased apoptosis of tumor cells and enhanced antitumor activity of immune cells via IFN-γ induction, making this cytokine a promising candidate for cancer therapy. Targeted expression of IL-12 within tumors has been shown to play a crucial role in tumor eradication. The recent development of oncolytic viruses enables targeted delivery and expression of IL-12 at the tumor site, thereby addressing the systemic toxicities associated with traditional cancer therapy. In this study, we constructed an oncolytic virus, VSVΔ51M, based on the commercially available VSV wild-type backbone and further modified it to express human IL-12. Our preclinical data confirmed the safety and limited toxicity of the modified virus, VSV-Δ51M-hIL-12, supporting its potential use for clinical development. (Copyright © 2023 Abdulal, Malki, Ghazal, Alsaieedi, Almahboub, Khan, Alsulaiman, Ghaith, Abujamel, Ganash, Mahmoud, Alkayyal and Hashem.) |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | J Virol. 2001 Dec;75(24):12169-81. (PMID: 11711608) Biotechnol J. 2006 Feb;1(2):138-47. (PMID: 16892244) Mol Biol Rep. 2019 Jun;46(3):3371-3379. (PMID: 31006094) Sci Transl Med. 2019 Aug 14;11(505):. (PMID: 31413142) Front Oncol. 2020 Mar 24;10:384. (PMID: 32266155) J Virol. 2013 Sep;87(18):10283-94. (PMID: 23864625) Cancer Gene Ther. 2012 Apr;19(4):238-46. (PMID: 22158521) Oncogene. 2005 Nov 21;24(52):7710-9. (PMID: 16299531) Viruses. 2019 Aug 22;11(9):. (PMID: 31443406) Cancers (Basel). 2021 Jan 06;13(2):. (PMID: 33418929) Cancers (Basel). 2021 Aug 25;13(17):. (PMID: 34503097) Cancer Immunol Res. 2017 Mar;5(3):211-221. (PMID: 28159747) Otolaryngol Head Neck Surg. 2007 May;136(5):811-7. (PMID: 17478221) Science. 1994 Jun 24;264(5167):1918-21. (PMID: 8009221) BMC Bioinformatics. 2017 Nov 29;18(1):529. (PMID: 29187165) Semin Oncol Nurs. 2019 Oct;35(5):150923. (PMID: 31526550) Cancer Gene Ther. 2010 Dec;17(12):883-92. (PMID: 20725101) J Virol. 2012 Mar;86(6):3073-87. (PMID: 22238308) J Virol. 2018 Nov 12;92(23):. (PMID: 30232179) Nat Rev Immunol. 2022 Mar;22(3):158-172. (PMID: 34155388) Future Virol. 2010;5(1):85-96. (PMID: 23516023) Mol Ther. 2013 Oct;21(10):1930-7. (PMID: 23842448) Transl Res. 2021 Nov;237:98-123. (PMID: 33905949) Clin Cancer Res. 2016 Jun 15;22(12):2969-80. (PMID: 26755531) Hum Gene Ther. 2011 Nov;22(11):1343-53. (PMID: 21366404) Mol Ther Oncolytics. 2016 Feb 17;3:16001. (PMID: 27119116) Cancer Cell. 2003 Oct;4(4):263-75. (PMID: 14585354) Mol Ther. 2012 Sep;20(9):1791-9. (PMID: 22760544) Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12):. (PMID: 29101107) Nat Commun. 2015 Mar 30;6:6410. (PMID: 25817275) J Gen Virol. 2017 Dec;98(12):2895-2911. (PMID: 29143726) Curr Top Microbiol Immunol. 2005;292:165-200. (PMID: 15981472) F1000Res. 2015 Dec 17;4:. (PMID: 26918147) J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32209602) PLoS One. 2015 Jun 19;10(6):e0131137. (PMID: 26091335) J Immunol. 1992 Jun 1;148(11):3433-40. (PMID: 1350290) Sci Transl Med. 2020 Jan 15;12(526):. (PMID: 31941828) J Gen Virol. 2010 Nov;91(Pt 11):2782-93. (PMID: 20631091) J Gen Virol. 2018 Apr;99(4):447-448. (PMID: 29465028) Oncolytic Virother. 2015 Oct 15;4:157-67. (PMID: 27512679) J Vasc Interv Radiol. 2012 May;23(5):704-11. (PMID: 22387029) |
| Contributed Indexing: | Keywords: B16F10; MCF-7; VSVΔ51M; cancer immunotherapy; interleukin-12; oncolytic virus |
| Entry Date(s): | Date Created: 20230531 Latest Revision: 20230601 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10225647 |
| DOI: | 10.3389/fmolb.2023.1190669 |
| PMID: | 37255540 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!